Biolex Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1997-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.biolex.com
480 STUDY: Phase 2b Study of Locteron Plus Ribavirin to Treat Hepatitis C Virus (HCV)
- First Posted Date
- 2009-08-06
- Last Posted Date
- 2012-02-02
- Lead Sponsor
- Biolex Therapeutics, Inc.
- Target Recruit Count
- 74
- Registration Number
- NCT00953589
- Locations
- 🇧🇬
Tokuda Hospital, Sofia, Bulgaria
🇷🇴Fundeni Clinical Institute, Bucharest, Romania
🇧🇬UMHAT "St Maria", Varna, Bulgaria
Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-03-17
- Last Posted Date
- 2012-02-02
- Lead Sponsor
- Biolex Therapeutics, Inc.
- Target Recruit Count
- 116
- Registration Number
- NCT00863239
- Locations
- 🇺🇸
The Liver Institute at Methodist Dallas, Dallas, Texas, United States
🇧🇬UMHAT "St Marina", Varna, Bulgaria
🇺🇸eStudy Site, Oceanside, California, United States
Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-01-14
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Biolex Therapeutics, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT00593151
- Locations
- 🇺🇸
Alamo Medical Research, San Antonio, Texas, United States
🇺🇸Inova Center for Liver Diseases, Annandale, Virginia, United States
🇺🇸Henry Ford Hospital, Detroit, Michigan, United States
© Copyright 2024. All Rights Reserved by MedPath